279 related articles for article (PubMed ID: 22439615)
1. Halogen-enriched fragment libraries as leads for drug rescue of mutant p53.
Wilcken R; Liu X; Zimmermann MO; Rutherford TJ; Fersht AR; Joerger AC; Boeckler FM
J Am Chem Soc; 2012 Apr; 134(15):6810-8. PubMed ID: 22439615
[TBL] [Abstract][Full Text] [Related]
2. Exploiting Transient Protein States for the Design of Small-Molecule Stabilizers of Mutant p53.
Joerger AC; Bauer MR; Wilcken R; Baud MGJ; Harbrecht H; Exner TE; Boeckler FM; Spencer J; Fersht AR
Structure; 2015 Dec; 23(12):2246-2255. PubMed ID: 26636255
[TBL] [Abstract][Full Text] [Related]
3. Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm.
Bauer MR; Krämer A; Settanni G; Jones RN; Ni X; Khan Tareque R; Fersht AR; Spencer J; Joerger AC
ACS Chem Biol; 2020 Mar; 15(3):657-668. PubMed ID: 31990523
[TBL] [Abstract][Full Text] [Related]
4. A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C.
Bauer MR; Jones RN; Tareque RK; Springett B; Dingler FA; Verduci L; Patel KJ; Fersht AR; Joerger AC; Spencer J
Future Med Chem; 2019 Oct; 11(19):2491-2504. PubMed ID: 31633398
[No Abstract] [Full Text] [Related]
5. Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines.
Baud MGJ; Bauer MR; Verduci L; Dingler FA; Patel KJ; Horil Roy D; Joerger AC; Fersht AR
Eur J Med Chem; 2018 May; 152():101-114. PubMed ID: 29702446
[TBL] [Abstract][Full Text] [Related]
6. Halogen-enriched fragment libraries as chemical probes for harnessing halogen bonding in fragment-based lead discovery.
Zimmermann MO; Lange A; Wilcken R; Cieslik MB; Exner TE; Joerger AC; Koch P; Boeckler FM
Future Med Chem; 2014 Apr; 6(6):617-39. PubMed ID: 24895892
[TBL] [Abstract][Full Text] [Related]
7. Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant.
Basse N; Kaar JL; Settanni G; Joerger AC; Rutherford TJ; Fersht AR
Chem Biol; 2010 Jan; 17(1):46-56. PubMed ID: 20142040
[TBL] [Abstract][Full Text] [Related]
8. Experimental and Theoretical Evaluation of the Ethynyl Moiety as a Halogen Bioisostere.
Wilcken R; Zimmermann MO; Bauer MR; Rutherford TJ; Fersht AR; Joerger AC; Boeckler FM
ACS Chem Biol; 2015 Dec; 10(12):2725-32. PubMed ID: 26378745
[TBL] [Abstract][Full Text] [Related]
9. Wild type p53 function in p53
Sundar D; Yu Y; Katiyar SP; Putri JF; Dhanjal JK; Wang J; Sari AN; Kolettas E; Kaul SC; Wadhwa R
J Exp Clin Cancer Res; 2019 Feb; 38(1):103. PubMed ID: 30808373
[TBL] [Abstract][Full Text] [Related]
10. Harnessing Fluorine-Sulfur Contacts and Multipolar Interactions for the Design of p53 Mutant Y220C Rescue Drugs.
Bauer MR; Jones RN; Baud MG; Wilcken R; Boeckler FM; Fersht AR; Joerger AC; Spencer J
ACS Chem Biol; 2016 Aug; 11(8):2265-74. PubMed ID: 27267810
[TBL] [Abstract][Full Text] [Related]
11. Multifunctional metallochaperone modifications for targeting subsite cavities in mutant p53-Y220C.
Miller JJ; Kwan K; Blanchet A; Orvain C; Mellitzer G; Smith J; Lento C; Nouchikian L; Omoregbee-Leichnitz S; Sabatou M; Wilson D; Gaiddon C; Storr T
J Inorg Biochem; 2023 May; 242():112164. PubMed ID: 36871418
[TBL] [Abstract][Full Text] [Related]
12. Multifunctional Compounds for Activation of the p53-Y220C Mutant in Cancer.
Miller JJ; Orvain C; Jozi S; Clarke RM; Smith JR; Blanchet A; Gaiddon C; Warren JJ; Storr T
Chemistry; 2018 Dec; 24(67):17734-17742. PubMed ID: 30230059
[TBL] [Abstract][Full Text] [Related]
13. Embracing the Diversity of Halogen Bonding Motifs in Fragment-Based Drug Discovery-Construction of a Diversity-Optimized Halogen-Enriched Fragment Library.
Heidrich J; Sperl LE; Boeckler FM
Front Chem; 2019; 7():9. PubMed ID: 30834240
[TBL] [Abstract][Full Text] [Related]
14. Effect of Y220C mutation on p53 and its rescue mechanism: a computer chemistry approach.
Rauf SM; Endou A; Takaba H; Miyamoto A
Protein J; 2013 Jan; 32(1):68-74. PubMed ID: 23315175
[TBL] [Abstract][Full Text] [Related]
15. Anticancer therapeutic strategies for targeting mutant p53-Y220C.
Chasov V; Davletshin D; Gilyazova E; Mirgayazova R; Kudriaeva A; Khadiullina R; Yuan Y; Bulatov E
J Biomed Res; 2024 May; 38(3):222-232. PubMed ID: 38738269
[TBL] [Abstract][Full Text] [Related]
16. Quadruple Target Evaluation of Diversity-Optimized Halogen-Enriched Fragments (HEFLibs) Reveals Substantial Ligand Efficiency for AP2-Associated Protein Kinase 1 (AAK1).
Dammann M; Kramer M; Zimmermann MO; Boeckler FM
Front Chem; 2021; 9():815567. PubMed ID: 35186897
[TBL] [Abstract][Full Text] [Related]
17. Small molecule induced reactivation of mutant p53 in cancer cells.
Liu X; Wilcken R; Joerger AC; Chuckowree IS; Amin J; Spencer J; Fersht AR
Nucleic Acids Res; 2013 Jul; 41(12):6034-44. PubMed ID: 23630318
[TBL] [Abstract][Full Text] [Related]
18. Structures of oncogenic, suppressor and rescued p53 core-domain variants: mechanisms of mutant p53 rescue.
Wallentine BD; Wang Y; Tretyachenko-Ladokhina V; Tan M; Senear DF; Luecke H
Acta Crystallogr D Biol Crystallogr; 2013 Oct; 69(Pt 10):2146-56. PubMed ID: 24100332
[TBL] [Abstract][Full Text] [Related]
19. An in silico algorithm for identifying stabilizing pockets in proteins: test case, the Y220C mutant of the p53 tumor suppressor protein.
Bromley D; Bauer MR; Fersht AR; Daggett V
Protein Eng Des Sel; 2016 Sep; 29(9):377-90. PubMed ID: 27503952
[TBL] [Abstract][Full Text] [Related]
20. Revisiting a challenging p53 binding site: a diversity-optimized HEFLib reveals diverse binding modes in T-p53C-Y220C.
Stahlecker J; Klett T; Schwer M; Jaag S; Dammann M; Ernst LN; Braun MB; Zimmermann MO; Kramer M; Lämmerhofer M; Stehle T; Coles M; Boeckler FM
RSC Med Chem; 2022 Dec; 13(12):1575-1586. PubMed ID: 36561072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
